Apr 2, 2024
Observations of Recent China related biotech BD/M&A deals By Dr. Bing Li
Dr. Bing Li will share his thoughts on the recent China biotech related deals, focusing on BD/M&A deal structure types, financial and operation implications to small biotech, key success factors for deal making. He will also offer the discussion on small biotech exit paths when successful IPO is far from reach.
This event is Free !
This event is over.
Date and Time
April 2, 2024, 4:30 pm - 7:30 pmLocation
Denovo Biopharma, 10240 Science Center Drive, San Diego, CA 92121About this Event
Agenda:
16:30 Light dinner and social networking
17:00 Introducing SABPA EPC and speaker
17:05 Oberservations of Recent China related Biotech BD/M&A deals
(Dr. Bing Li, CEO of Shanto Pharma)
18:00 Open discussion and social networking
19:30 Adjourn
-
Free food and drink will be provided.
-
Onsite venue limited to 50 participants on a first-come-first-serve basis.
-
Registration required; Free of charge.
-
https://sabpa.org/member/event.php?id=100125
Speaker:
Bing Li, Ph.D.
CEO, Shanto Pharma
Interim CEO, KBP Biosciences
Prior to Shanton Pharma and KBP Biosciences, Dr. Bing Li was the founding CEO of LianBio (Nasdaq listed: LIAN). Previously, Dr. Li also served as CEO for China Biologic Products (Nasdaq listed: CBPO). Dr. Li was also the Vice President and Managing Director of Fosun Health Holding, leading Global Healthcare PE Investment Team of Fosun Group, also Vice President and International Department General Manager for Fosunpharma, in charge of oversea investment and M&A. Dr. Li joined Fosun Group from Warburg Pincus, where he co-led Warburg Pincus healthcare practice in China. Prior to Warburg Pincus, Dr. Li was General Manager, GSK China Enterprise where he led the Enterprise Business Unit and overall BD/Strategy function for GSK China. At the beginning of his career, Dr. Li also worked at global headquarter of Eli Lilly and advanced his career from multiple roles including strategic planning, business development and new product planning.
Dr. Li led the completion of various significant projects in healthcare field, including: (1) multiple JV and acquisition deals for GSK, (2) $200+ Million private placements and successful total $1+ billion exits of three Chinese biopharma companies for Warburg Pincus, (3) buyout and restructure of Ambrx by Chinese investor consortium, and formation of Fosun/Kite Car T Joint Venture, for Fosun Group, (4) Asset acquisition transaction of Ocedurenone between Novo Nordisk and KBP Biosciences, representing KBP. Dr. Li has previously served as the Chairman of the Board of Ambrx, and on the boards of many biotech and pharma companies. Dr. Li received his Ph.D. in Biologic Science from the University of Rochester, MBA/MEM from Kellogg School of Management, B.S. from Fudan University.
SABPA Entrepreneurship and Partnering Committee (EPC) monthly salon is a new event that aims to create a local ecosystem that supports and empower entrepreneurs by providing them with the necessary resources, guidance, and networking opportunities to succeed in their ventures. The event is held on every first Wednesday of the month.
